Citi lowered the firm’s price target on Apellis (APLS) to $51 from $63 and keeps a Buy rating on the shares post the Q3 report. The firm says that with the stock re-rating in 2024, there’s a “clear opportunity to reconstruct a ‘post-GA’ thesis” anchored on high conviction in C3G and IC-MPGN, where it beeves the data are “resoundingly strong and outshine the oral competitor and in a broader setting.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $30 from $43 at Wells Fargo
- Apellis price target lowered to $47 from $61 at BofA
- Apellis price target lowered to $57 from $83 at H.C. Wainwright
- Apellis Pharmaceuticals Reports Revenue Growth Amid Ongoing Investments
- Apellis price target lowered to $75 from $84 at Stifel